SAVA vs. IRWD, ELVN, ARQT, GYRE, LQDA, VRNA, INVA, COLL, ABCL, and TYRA Should you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Ironwood Pharmaceuticals (IRWD), Enliven Therapeutics (ELVN), Arcutis Biotherapeutics (ARQT), Gyre Therapeutics (GYRE), Liquidia (LQDA), Verona Pharma (VRNA), Innoviva (INVA), Collegium Pharmaceutical (COLL), AbCellera Biologics (ABCL), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
Ironwood Pharmaceuticals (NASDAQ:IRWD ) and Cassava Sciences (NASDAQ:SAVA ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
Ironwood Pharmaceuticals received 409 more outperform votes than Cassava Sciences when rated by MarketBeat users. However, 66.43% of users gave Cassava Sciences an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
Ironwood Pharmaceuticals currently has a consensus target price of $18.40, indicating a potential upside of 183.51%. Cassava Sciences has a consensus target price of $131.00, indicating a potential upside of 492.22%. Given Ironwood Pharmaceuticals' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.
Cassava Sciences has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Cassava Sciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cassava Sciences has a net margin of 0.00% compared to Cassava Sciences' net margin of -254.41%. Cassava Sciences' return on equity of -28.45% beat Ironwood Pharmaceuticals' return on equity.
In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Ironwood Pharmaceuticals and 5 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.62 beat Ironwood Pharmaceuticals' score of 0.43 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.
38.1% of Cassava Sciences shares are held by institutional investors. 13.1% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary Ironwood Pharmaceuticals beats Cassava Sciences on 10 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Cassava Sciences Competitors List
Related Companies and Tools
